Discovery® Antibodies is Cambridge Research Biochemicals' catalogue antibody business.
CRB, the 2nd oldest peptide company in the world and forerunner in the antibody research market is now building a collection of newly validated target antibodies under the banner of Discovery® Antibodies.
Discovery® Antibodies will focus on antibodies for research (early drug ‘discovery’) and will complement our very successful and long-standing custom antibody business (www.crbdiscovery.com). We are already well known for novel, complex, rare and post-translational modification specific antibodies and these sought after targets will feature in our Discovery® Antibody catalogue range.
We launched our Discovery® Antibodies in February 2017 a year after Discovery® Peptides and some 240 years after Captain James Cook, (the greatest explorer of his time) set off in 1776 from England aboard the ‘HMS Discovery’ to charter new waters and ‘discover’ new lands around the globe. Thus the name ‘Discovery’ seemed fitting to a North-East-based manufacturer – the home town of James Cook.
Further parallels arise between the quest for new found lands around the world in the late 1700s and new ‘discoveries’ in medical research and the mapping of the human genome in 2000.
For further details please see our press release on the launch of Discovery® Antibodies
Cambridge Research Biochemicals (www.crbdiscovery.com) founded in 1980 is a leading British independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus. In 2016 the company launched its first catalogue business DISCOVERY® since 1994.